| Title |
Management of Statin Intolerance in 2018: Still More Questions Than Answers
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, January 2018
|
| DOI | 10.1007/s40256-017-0259-7 |
| Pubmed ID | |
| Authors |
Peter P. Toth, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Giuseppa Castellino, Manfredi Rizzo, Maciej Banach |
| Abstract |
Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins-even at the lowest dose-non-statin drugs and certain nutraceuticals can be considered. This review focuses on the definition of statin intolerance and on the development of clinical and therapeutic strategies for its management, including emerging alternative therapies. |
X Demographics
The data shown below were collected from the profiles of 30 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Poland | 5 | 17% |
| Spain | 4 | 13% |
| United States | 3 | 10% |
| United Kingdom | 2 | 7% |
| France | 2 | 7% |
| Japan | 1 | 3% |
| Colombia | 1 | 3% |
| Unknown | 12 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 73% |
| Scientists | 4 | 13% |
| Practitioners (doctors, other healthcare professionals) | 3 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 190 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 190 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 12% |
| Student > Master | 21 | 11% |
| Other | 17 | 9% |
| Student > Bachelor | 17 | 9% |
| Student > Ph. D. Student | 16 | 8% |
| Other | 32 | 17% |
| Unknown | 65 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 12% |
| Biochemistry, Genetics and Molecular Biology | 22 | 12% |
| Agricultural and Biological Sciences | 9 | 5% |
| Nursing and Health Professions | 8 | 4% |
| Other | 10 | 5% |
| Unknown | 74 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 208. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2023.
All research outputs
#187,000
of 25,386,440 outputs
Outputs from American Journal of Cardiovascular Drugs
#2
of 467 outputs
Outputs of similar age
#4,299
of 457,201 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#2
of 5 outputs
Altmetric has tracked 25,386,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 467 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,201 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.